CRMD Stock — CorMedix Inc

CorMedix Inc (CRMD)

Updated October 16, 2026.

CRMD is a Stock. Total return is -51.6% over the past 16.4 years, 831.9 points behind SPY at 780.3%.

CorMedix Inc. is a biopharmaceutical company developing therapeutic products for life-threatening diseases, with its lead product candidate being DefenCath, an antimicrobial catheter lock solution designed to reduce catheter-related bloodstream infections in kidney failure patients. The company does not currently distribute to shareholders. CorMedix appeals primarily to investors seeking exposure to early-stage biopharmaceutical development rather than those focused on income generation.

CRMD performance versus SPY

Price and return data through 2026-10-16.

Total return is -51.6% over the past 16.4 years, 831.9 points behind SPY at 780.3%. Over the past year its total return — price change plus distributions reinvested — is -28.0%. Its deepest 1-year drawdown was 50.9%.

CRMD key facts

Asset type

Stock

Asset class

Equity

Inception date

05/13/2010

Distribution frequency

None

Last close

$7.26 (as of 2026-10-16)

Market cap

$565,875,792

Average volume

1140448.0

Payment date

03/26/2019

Beta

1.406

Payout ratio

0.0%

P/E ratio

3.58

Forward P/E

46.5116

EPS

$2.03

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

CRMD risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 50.9%.

Who may consider CRMD — and who may not

It is a weaker fit for investors who need monthly cash flow (CRMD does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on CRMD

• All tickers starting with C

Tagged: Healthcare.

Frequently asked questions